More recently, a peptide activator of the CaSR (AMG-416; L-Cys-AcDCys-DAla-(DArg)2-DAla-DArgNH2) has entered clinical practice for the treatment of patients with secondary hyperparathyroidism on hemodialysis (Bell et al., 2015). This evidence concerns the gene CASR and secondary hyperparathyroidism.